The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Unfortunately, I’m not sure that there’s a massive pool of competent AIM Biotech CEOs who don’t have any notice period to work and are super keen to jump on board with their seemingly failing business. There’s been lots of criticism over Suzy’s salary but were we really likely to get anyone competent on the cheap?
Nice one Badsterman. Clearly EUDA is out of cash. Why are the executives converting their debt claims in the company into shares which rank behind debts in priority on a winding up? Surely this has to mean that they think there’s upside likely to be realised in future?
Whilst I have proven time and time and time again to be excessively optimistic, maybe this heralds the good news we have been waiting for. Executives now incentivised with shares. Deal around the corner. Lots of joyous Valirx millionaires in time for Spring.
For what it’s worth, the end of today marks six months since the EUDA merger notification. Whilst highly unlikely, I’m still hopeful for an update at 9am NY time.
I like being disappointed…
Hmm have to hold my hands up, seems like I got it wrong on EUDA.
What next…
Good luck all, have a good Easter.
Porky - I was simply speculating on the reason for the EUDA share price moves last week.
Some of the EUDA loan notes convert at the end of the coming week if not settled. Share price increases are presumably due to investors thinking the TRx deal will go ahead before conversion. If it doesn’t, I’d expect a significant share price fall the following week.
Key questions for me are:
1. Does Suzy retain her share options? If so, do we risk a massive dilution if a new CEO needs more options for incentivisation?
2. Does this mean the 201 deal is dead? Seems like an odd time to give up if this completing is truly around the corner.
Big investor reducing its position in EUDA, not sure I like it:
————
Hudson Bay Capital Management LP Sells 760,500 Shares of EUDA Health Holdings Limited (NASDAQ:EUDA)
Do we know if Adam is part of the gang that sought to oust certain board members or not?
If not, and given his silence and lack of any material sell-down of his holding, I wonder what he might know that we don’t.
I still have a tiny bit of hope… it’s very little though
Starting to think my 31 March prediction for EUDA merger might be wide of the mark. My £25k in is now a bit over £3k. Whoops.
Any other crazy investment ideas to sink my cash into? I’m bored with this one
Are we expecting an update from management any time soon? Any q&as in the diary?
Interesting find, Badsterman... worth pointing out that these are different to the notes expected to be converted at 31 March 2024. These ones would have converted at $5 per share, which would presumably have been very bad news for the holder had they decided to convert (given share price is so much lower)
I'm amazed that EUDA has not been required to post any sort of market update on the TRx merger, given the previous announcement (along with timeframe) was quite a significant factor in the increase in its share price. Logically, the negotiations have to be ongoing in some shape or form, otherwise there would be an announcement... but I suppose there's a bigger question as to whether they have hit a dead-end in their negotiations.
Really hope there will be an update soon, so I (and others) can make an informed decision about what to do with shares and votes.
Honestly, all this FCA stuff is nonsense. We have made bets in a risky company and it hasn’t yet worked out. Nobody is going to be paying us compensation if it fails. Live and learn and, in the meantime, hope that 201 comes good.
Tanvier Malik seems to be behind Sanderson:
https://www.theinvestmentobserver.co.uk/companies/2018/03/12/beaufort-securities-scandal/
To be fair NH, that's quite an impressively low number of trades! Guess everyone's waiting to see what Suzy's response to the shareholders will be before selling or buying.
Was anticipating a big swing either way in the share price today, but it's pretty meh.
I do think Suzy has been naive in her approach to TRx, but I entirely disagree with the posters implying she's a swindler. Identification of new drugs is a business which will only burn cash unless/until an asset is monetised... clearly disappointing that VAL hasn't done that yet, but that really is the business model. The only hope (outside of drug monetisation) for cash coming in is the lab. If people don't understand this, they really shouldn't be invested in this share.
Fair enough all. The shareholders have taken action and I assume that a vote will therefore go ahead. I would just ask that the relevant shareholders now constructively engage with the BOD to determine whether the vote should happen either (I) ASAP, to resolve uncertainty in the TRx relationship; or, failing that, (ii) 1 April.
I don’t see any point in stringing this out long after the end of March.
Agreed NH, there is no 31 March deadline we are aware of. That said, if the merger does not complete by then, EUDA’s convertible loan notes suddenly become very expensive.
My nervousness is around the interdependencies here. If Val201 is an important reason for the merger, then uncertainty around whether any future board will pull out of the Val201 deal could mean that the merger cannot complete until the VAL board vote concludes. However, the board vote will likely be for Suzy to stay only if the merger goes ahead.
So, my concern is that by taking action now, the VAL shareholders may have scuppered the deal. Timing not sensible in my view
It does make me nervous that this is happening such a short time before the apparent deadline for EUDA-TRx merger. If (big if) that goes ahead by 31 March, I wonder how the uncertainty of any vote could impact on that relationship
Flip-side, I guess, is that this sends a strong message to TRx that the time for waiting is over. Does anyone have a view on how quickly a vote might take place? April Fools Day would frankly be perfect